Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
- PMID: 26438120
- PMCID: PMC4979132
- DOI: 10.1200/JCO.2015.61.7142
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Abstract
Purpose: Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers.
Patients and methods: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS).
Results: Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%).
Conclusion: To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients.
© 2015 by American Society of Clinical Oncology.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest are found in the article online at
Figures
![Fig 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4979132/bin/zlj9991056200001.gif)
![Fig 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4979132/bin/zlj9991056200002.gif)
![Fig A1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4979132/bin/zlj9991056200003.gif)
![Fig A2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4979132/bin/zlj9991056200004.gif)
Similar articles
-
Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.J Clin Oncol. 2010 Nov 1;28(31):4730-9. doi: 10.1200/JCO.2009.27.7665. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855822
-
A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.Eur J Cancer. 2013 Sep;49(13):2859-68. doi: 10.1016/j.ejca.2013.04.018. Epub 2013 Jun 1. Eur J Cancer. 2013. PMID: 23735705
-
Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e105-12. doi: 10.1016/j.clml.2015.02.027. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25817937
-
Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?Br J Dermatol. 2014 Jun;170(6):1226-36. doi: 10.1111/bjd.12909. Br J Dermatol. 2014. PMID: 24641480 Review.
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
Cited by
-
A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments.Antibodies (Basel). 2024 Apr 22;13(2):32. doi: 10.3390/antib13020032. Antibodies (Basel). 2024. PMID: 38804300 Free PMC article. Review.
-
Tumor Stage Mycosis Fungoides with Lymph Node Involvement.Kans J Med. 2024 Apr 26;17:39-40. doi: 10.17161/kjm.vol17.21453. eCollection 2024. Kans J Med. 2024. PMID: 38694178 Free PMC article. No abstract available.
-
Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon.Blood Adv. 2024 May 28;8(10):2384-2397. doi: 10.1182/bloodadvances.2023010043. Blood Adv. 2024. PMID: 38489234 Free PMC article.
-
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE): Protocol for a Translational Study.JMIR Res Protoc. 2024 Apr 4;13:e55723. doi: 10.2196/55723. JMIR Res Protoc. 2024. PMID: 38436589 Free PMC article.
-
Immunosequencing applications in cutaneous T-cell lymphoma.Front Immunol. 2023 Dec 21;14:1300061. doi: 10.3389/fimmu.2023.1300061. eCollection 2023. Front Immunol. 2023. PMID: 38213330 Free PMC article. Review.
References
-
- Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood. 2007;110:1713–1722. - PubMed
-
- Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785. - PubMed
-
- Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857–866. - PubMed
-
- Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: Where are we now? Br J Dermatol. 2014;170:1226–1236. - PubMed
-
- Benner MF, Jansen PM, Vermeer MH, et al. Prognostic factors in transformed mycosis fungoides: A retrospective analysis of 100 cases. Blood. 2012;119:1643–1649. - PubMed